Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/Ritonavir for Omicron COVID-19
NCT05813600Completed
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Nasal swab COVID-19 nucleic acid tests at Day 11, Virus turn negative up to 5 months and 3 more. Started Aug 2022; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05813600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813600.